• Cheelcare posted fiscal 2026 revenue of CAD 1.9 million, up 22%, as Companion unit sales rose 18% to 536.
• Net loss widened to CAD 4.86 million, or CAD 0.27 per share, from CAD 1.27 million, or CAD 0.12 per share.
• Gross profit fell to CAD 464,525, cutting gross margin to 24% from 42%, due to a CAD 443,000 inventory write-off.
• Fourth-quarter revenue climbed 78% to CAD 628,407, while gross result swung to a loss of CAD 185,033 on the write-off.
• Management cited improved Companion sales activity since January’s PDAC verification enabling U.S. Medicare and Medicaid reimbursement eligibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cheelcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608310730NEWSFILECNPR____20260831_312086_1) on August 31, 2026, and is solely responsible for the information contained therein.